Zhejiang Key Laboratory of RNA Medicine Intelligence

Zhejiang Key Laboratory of RNA Medicine Intelligence is led by the RNA Medicine Center of Zhejiang University. It focuses on critical technological breakthroughs in the intelligent design and efficient delivery of RNA therapeutics, aiming to address China’s—particularly Zhejiang Province’s—strategic needs in the field of RNA medicine. In recent years, RNA drug technologies have seen rapid development, especially with the success of mRNA vaccines, which have accelerated global interest in RNA-based therapies. However, domestic progress still faces challenges in original drug design, delivery material innovation, and intellectual property strategy.

The laboratory integrates artificial intelligence, big data, and RNA drug research to build a full-chain R&D platform encompassing sequence recognition, structural design, delivery optimization, and in vivo validation. The team has developed China’s first RNA sequence foundation model, GenePT, and completed a portfolio of patents on LNP delivery materials, with several technologies adopted by international pharmaceutical companies. The laboratory houses a 3,200-square-meter modern research facility, including an animal center, high-performance computing infrastructure, and translational medicine support, enabling both original innovation and product pipeline incubation.

Professor Xin Li, the laboratory director, holds international recognition in RNA stability, transgenerational inheritance, and big data-driven disovery. The academic committee includes renowned experts such as Academician Lynne Maquat and Professor Xiangdong Fu. Over the next three years, the lab will advance RNA drug mechanism research and candidate pipelines in reproductive health, metabolic disorders, and pulmonary infections, aiming to tackle clinical challenges such as infertility. The goal is to establish a globally influential innovation hub for RNA medicine and contribute core scientific support to China’s “Healthy China” strategy.